The proteome signature of the inflammatory breast cancer plasma membrane identifies novel molecular markers of disease

Ivette J. Suárez-Arroyo, Yismeilin R. Feliz-Mosquea, Juliana Pérez-Laspiur, Rezina Arju, Shah Giashuddin, Gerónimo Maldonado-Martínez, Luis A. Cubano, Robert J. Schneider, Michelle M. Martínez-Montemayor

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Inflammatory Breast Cancer (IBC) is the most lethal form of breast cancer with a 35% 5-year survival rate. The accurate and early diagnosis of IBC and the development of targeted therapy against this deadly disease remain a great medical challenge. Plasma membrane proteins (PMPs) such as E-cadherin and EGFR, play an important role in the progression of IBC. Because the critical role of PMPs in the oncogenic processes they are the perfect candidates as molecular markers and targets for cancer therapies. In the present study, Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) followed by mass spectrometry analysis was used to compare the relative expression levels of membrane proteins (MP) between non-cancerous mammary epithelial and IBC cells, MCF-10A and SUM-149, respectively. Six of the identified PMPs were validated by immunoblotting using the membrane fractions of non-IBC and IBC cell lines, compared with MCF-10A cells. Immunohistochemical analysis using IBC, invasive ductal carcinoma or normal mammary tissue samples was carried out to complete the validation method in nine of the PMPs. We identified and quantified 278 MPs, 76% of which classified as PMPs with 1.3-fold or higher change. We identified for the first time the overexpression of the novel plasminogen receptor, PLGRKT in IBC and of the carrier protein, SCAMP3. Furthermore, we describe the positive relationship between L1CAM expression and metastasis in IBC patients and the role of SCAMP3 as a tumor-related protein. Overall, the membrane proteomic signature of IBC reflects a global change in cellular organization and suggests additional strategies for cancer progression. Together, this study provides insight into the specialized IBC plasma membrane proteome with the potential to identify a number of novel therapeutic targets for IBC.

Original languageEnglish
Pages (from-to)1720-1740
Number of pages21
JournalAmerican Journal of Cancer Research
Issue number8
StatePublished - 2016
Externally publishedYes


  • IBC
  • IDC
  • L1CAM
  • Markers
  • Membrane
  • Proteomics
  • SCAMP3


Dive into the research topics of 'The proteome signature of the inflammatory breast cancer plasma membrane identifies novel molecular markers of disease'. Together they form a unique fingerprint.

Cite this